(Reuters) – Merck said on Wednesday it was scrapping research operations in London, citing the UK’s challenging business environment, and would relocate the research activity to existing sites primarily in the United States.

The U.S. drugmaker no longer plans to occupy the Belgrove House site at King’s Cross, which was due to open in 2027. The move will impact about 125 staff members.

Pharmaceutical companies have been shoring up investments in the U.S. amid the Trump administration’s tariff threats and pressure to move more manufacturing to the U.S.

Merck said its decision “reflects the challenges of the UK not making meaningful progress towards addressing the lack of investment in the life science industry and the overall undervaluation of innovative medicines and vaccines by successi

See Full Page